XENOBIOSYS
AI-Programmable Biotherapeutics
AI-Programmable Biotherapeutics
Smart Medicine for a New Era
Xenobiosys is pioneering Generation 3 Biotherapeutics. By coupling generative structural models with an integrated wet-lab feedback loop, we design programmable synthetic nanobodies and live biotherapeutic delivery systems with atomic precision.
Moving past the limitations of traditional small molecules and standard biologics through closed-loop molecular engineering.
Pure computational predictions fail without empirical ground truth. Our platform tightly integrates de novo generative models with internal bench testing, feeding real expression and binding data directly back into our fine-tuning loop.
By embedding negative-selection filters and structural liability screening directly into our computational stage, we systematically triage out non-specific binding and conformational instabilities before synthesis.
Hyper-specific single-domain scaffolds engineered to access recessed catalytic clefts and flat protein-protein interaction (PPI) interfaces that traditional immunoglobulins cannot engage.
At Xenobiosys, we believe the future of medicine lies in programmability. Our mission is to transform how therapeutic proteins are discovered, engineered, and delivered.
While Generation 1 (small molecules) and Generation 2 (biologics) transformed clinical care, both remain bound to empirical screening and what natural immune systems happen to evolve. Our Generation 3 paradigm treats molecular design as a deterministic discipline: computationally designing targeted proteins, validating them through continuous wet-lab feedback, and delivering them via autonomous biological systems.
Small-footprint single-domain proteins engineered for deep solid tumor penetration and specific engagement of tumor microenvironment targets.
Targeted disruption of auto-immune and inflammatory signaling complexes with high structural selectivity.
Precision-designed affinity scaffolds capable of neutralizing evolving viral and bacterial surface antigens to overcome resistance.
Our engineered single-domain proteins represent a major step forward in therapeutic protein design. Derived from heavy-chain camelid antibodies, synthetic nanobodies combine antibody-level specificity with the stability and manufacturability of small proteins.
Xenobiosys designs single-domain scaffolds with custom-tailored biophysical properties:
| Property | Traditional Antibodies | Xenobiosys Synthetic Nanobodies |
|---|---|---|
| Size | ~150 kDa | ~15 kDa (10x smaller) |
| Tissue Penetration | Limited | Deep tissue penetration |
| Thermal Stability | Moderate | High (up to 80°C) |
| Production Cost | High (mammalian cell culture) | Low (microbial fermentation) |
| Design & Iteration Time | 12-24 months | 2-6 months (Closed-loop AI to bench) |
Our nanobodies bind pathological protein targets with nanomolar to picomolar affinity, blocking disease pathways while sparing normal cellular function.
Compact and robust single-domain scaffolds serve as stable delivery vehicles for cytotoxic payloads, radioisotopes, or imaging agents directly to disease sites.
Modular engineering enables bi- and tri-specific constructs that simultaneously engage multiple epitopes or recruit immune effectors without heavy/light chain mispairing.
Live Biotherapeutic Products represent our ultimate delivery horizon. Rather than relying solely on repeated systemic injections that degrade rapidly in circulation, Xenobiosys engineers biological chassis to express and deliver smart biotherapeutics directly at the site of pathology.
Our long-term LBP platform combines synthetic biology with microbiome science to establish autonomous therapeutic delivery:
Engineered microbial chassis designed to survive physiological transit and colonize targeted tissue surfaces, providing continuous local production of our synthetic nanobodies without invasive IV administration.
Microbial delivery systems programmed with genetic biosensors that trigger therapeutic release strictly in response to local pathology markers (such as inflammation signals, altered pH, or disease metabolites).
Local in-situ synthesis circumvents rapid renal clearance and systemic toxicity, maintaining protective concentrations directly at the target interface while improving long-term patient compliance.
Our closed-loop computational and laboratory engine designs and validates stable, high-affinity nanobodies. Our LBP platform provides the biological vehicle to deliver them autonomously at the point of disease—fulfilling the vision of living, programmable medicine.
We are looking for strategic partners, co-developers, and visionary investors to advance Generation 3 Biotherapeutics from the lab bench to clinical impact.
Inquire for Partnerships